GlassScriptPhysician profile
Travis J Rudge
NPI 1336192962
$14,247.40
in general payments reported to CMS, 2019-2025
43 companies · $2,145 in 2025
The $2,145 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,838 · 2022: $3,009 · 2023: $3,205 · 2024: $3,050 · 2025: $2,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,400.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,817.89 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,610.27 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,217.35 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,155.80 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $1,154.68 | 2021-2025 | |
| Amgen INC. | $665.21 | 2021-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $578.71 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $472.68 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Biohaven Pharmaceutical Holding Company LTD. | $467.93 | 2022 | |
| Phathom Pharmaceuticals, INC. | $428.16 | 2023-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $360.33 | 2021-2025 | Verquvo, Belsomra, M-M-R II |
| Novartis Pharmaceuticals Corporation | $277.83 | 2021-2024 | |
| Biohaven Pharmaceuticals, INC. | $272.76 | 2021 | |
| Exact Sciences Corporation | $229.36 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $213.52 | 2021-2024 | Xarelto |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $208.74 | 2023-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $196.21 | 2021-2025 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $185.26 | 2021-2025 | Zoryve, Livalo, Seglentis |
| Abbott Laboratories | $177.90 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $170.71 | 2021-2024 | Veozah |
| Amarin Pharma, INC. | $142.70 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $128.88 | 2022-2024 | |
| Esperion Therapeutics, INC. | $126.31 | 2021-2025 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.29 | 2021-2025 | Xifaxan, Trulance |
| Ardelyx, INC. | $107.14 | 2025 | Ibsrela |
| Lundbeck LLC | $83.55 | 2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $81.42 | 2021-2022 | |
| Electromed, INC. | $61.98 | 2023-2025 | Smartvest |
| Exeltis, USA INC. | $61.72 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.16 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $48.65 | 2021 | |
| Biogen, INC. | $46.53 | 2021-2022 | |
| Eisai INC. | $46.40 | 2021-2024 | |
| Verona Pharma, INC. | $43.67 | 2025 | Ohtuvayre |
| Sage Therapeutics, LLC | $42.36 | 2025 | Zurzuvae |
| Dexcom, INC. | $40.45 | 2021-2023 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $37.16 | 2023-2024 | Accrufer |
| Teva Pharmaceuticals USA, INC. | $33.12 | 2021 | |
| Xeris Pharmaceuticals, INC. | $16.26 | 2023 | Gvoke Hypopen |
| Organon LLC | $16.08 | 2023 | Nexplanon |
| Lexicon Pharmaceuticals, INC. | $15.78 | 2023 | Inpefa |
| Ironwood Pharmaceuticals, INC | $15.44 | 2023 | Linzess |
| Collegium Pharmaceutical, INC. | $15.05 | 2023 | Xtampza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Rudge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.